{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:14:36Z","timestamp":1780586076286,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014565","name":"Bausch Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01734-w","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:27:30Z","timestamp":1776346050000},"page":"2931-2946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Canadian Treat-to-Target Practice Survey of Real-World Interventions and Strategies in Psoriasis (CAN TARGET PSORIASIS)"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7318-5515","authenticated-orcid":false,"given":"Jensen","family":"Yeung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9296-5851","authenticated-orcid":false,"given":"Parbeer","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla","family":"Lansang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-2724","authenticated-orcid":false,"given":"Ron","family":"Vender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9634-3750","authenticated-orcid":false,"given":"Marni","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8527-4163","authenticated-orcid":false,"given":"Rami Abou","family":"Zeinab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3000-2125","authenticated-orcid":false,"given":"Maxime","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-2522","authenticated-orcid":false,"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"1734_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis. JAMA. 2020;323:1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"key":"1734_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"JE Hawkes","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140:645\u201353. https:\/\/doi.org\/10.1016\/j.jaci.2017.07.004.","journal-title":"J Allergy Clin Immunol"},{"key":"1734_CR3","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/bjd.18635","volume":"182","author":"J Takeshita","year":"2020","unstructured":"Takeshita J. Taking aim at identifying treatment targets for psoriasis. Br J Dermatol. 2020;182:1075\u20136. https:\/\/doi.org\/10.1111\/bjd.18635.","journal-title":"Br J Dermatol"},{"key":"1734_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaad.2019.05.056","volume":"82","author":"P Lansang","year":"2020","unstructured":"Lansang P, Bergman JN, Fiorillo L, et al. Management of pediatric plaque psoriasis using biologics. J Am Acad Dermatol. 2020;82:213\u201321. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.056.","journal-title":"J Am Acad Dermatol"},{"key":"1734_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.36849\/JDD.2020.4957","volume":"19","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Wu J, Armstrong A, Menter A, Liu C, Jacobson A. Importance of complete skin clearance in psoriasis as a treatment goal: Implications for patient-reported outcomes. J Drugs Dermatol. 2020;19:487\u201392. https:\/\/doi.org\/10.36849\/JDD.2020.4957.","journal-title":"J Drugs Dermatol"},{"key":"1734_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/1346-8138.17249","volume":"51","author":"WJ Song","year":"2024","unstructured":"Song WJ, Yoon H. Impact of residual skin lesions and previous biologic treatment failure on patient-reported outcomes in patients with psoriasis receiving biologic treatment. J Dermatol. 2024;51:772\u20138. https:\/\/doi.org\/10.1111\/1346-8138.17249.","journal-title":"J Dermatol"},{"key":"1734_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15777","volume":"35","author":"J Yeung","year":"2022","unstructured":"Yeung J, Bourcier M, Gooderham MJ, et al. Management of moderate-to-severe plaque psoriasis with biologics: a treat-to-target position paper. Dermatol Ther. 2022;35:e15777. https:\/\/doi.org\/10.1111\/dth.15777.","journal-title":"Dermatol Ther"},{"key":"1734_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1\u201310. https:\/\/doi.org\/10.1007\/s00403-010-1080-1.","journal-title":"Arch Dermatol Res"},{"key":"1734_CR9","unstructured":"R Core Team. R: a language and environment for statistical computing. In: The R reference index. R Foundation for Statistical Computing. 2023. https:\/\/www.R-project.org. Accessed 2 Jun 2025"},{"key":"1734_CR10","unstructured":"Wickham H, Hester J, Bryan J. readr: Read rectangular text data. 2023. https:\/\/CRAN.R-project.org\/package=readr. Accessed 2 Jun 2025"},{"key":"1734_CR11","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. J Open Source Softw. 2019;4:1686. https:\/\/doi.org\/10.21105\/joss.01686.","journal-title":"J Open Source Softw"},{"key":"1734_CR12","unstructured":"Wickham H. ggplot2: Elegant graphics for data analysis. New York: Springer-Verlag; 2016. https:\/\/ggplot2.tidyverse.org. Accessed 2 Jun 2025"},{"key":"1734_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/PTT.S356568","volume":"12","author":"CC de Ruiter","year":"2022","unstructured":"de Ruiter CC, Rustemeyer T. Biologics can significantly improve dermatology life quality index (DLQI) in psoriatic patients: a systematic review. Psoriasis (Auckl). 2022;12:99\u2013112. https:\/\/doi.org\/10.2147\/PTT.S356568.","journal-title":"Psoriasis (Auckl)"},{"key":"1734_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/09546634.2017.1289147","volume":"28","author":"JM Norlin","year":"2017","unstructured":"Norlin JM, Calara PS, Persson U, Schmitt-Egenolf M. Real-world outcomes in 2646 psoriasis patients: one in five has PASI \u226510 and\/or DLQI \u226510 under ongoing systemic therapy. J Dermatolog Treat. 2017;28:500\u20134. https:\/\/doi.org\/10.1080\/09546634.2017.1289147.","journal-title":"J Dermatolog Treat"},{"key":"1734_CR15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2147\/CCID.S396997","volume":"16","author":"J Yang","year":"2023","unstructured":"Yang J, Hu K, Li X, et al. Psoriatic foot involvement is the most significant contributor to the inconsistency between PASI and DLQI: a retrospective study from China. Clin Cosmet Investig Dermatol. 2023;16:443\u201351. https:\/\/doi.org\/10.2147\/CCID.S396997.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1734_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216424","volume":"13","author":"N Rompoti","year":"2024","unstructured":"Rompoti N, Tsiori S, Kontoangelos K, et al. Psychopathological profile of patients with moderate-to-severe plaque psoriasis and its correlation to DLQI: results from a prospective, monocentric clinical study. J Clin Med. 2024;13:6424. https:\/\/doi.org\/10.3390\/jcm13216424.","journal-title":"J Clin Med"},{"key":"1734_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/j.1365-2133.2010.09999.x","volume":"163","author":"AD Ormerod","year":"2010","unstructured":"Ormerod AD. Switching biologics for psoriasis. Br J Dermatol. 2010;163:667\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09999.x.","journal-title":"Br J Dermatol"},{"key":"1734_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17512433.2020.1767590","volume":"13","author":"Y-C Tsai","year":"2020","unstructured":"Tsai Y-C, Tsai T-F. Switching biologics in psoriasis\u2014practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13:493\u2013503. https:\/\/doi.org\/10.1080\/17512433.2020.1767590.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1734_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/1346-8138.16214","volume":"49","author":"MJ Gooderham","year":"2022","unstructured":"Gooderham MJ, Lynde C, Turchin I, Avadisian M, Labelle M, Papp KA. Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. J Dermatol. 2022;49:95\u2013105. https:\/\/doi.org\/10.1111\/1346-8138.16214.","journal-title":"J Dermatol"},{"key":"1734_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2200870","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Patel M, Li C, Garg V, Mandava MR, Wu JJ. Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States. J Dermatolog Treat. 2023. https:\/\/doi.org\/10.1080\/09546634.2023.2200870.","journal-title":"J Dermatolog Treat"},{"key":"1734_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2299598","author":"C Miyazaki","year":"2024","unstructured":"Miyazaki C, Masuda J, Rodriguez-Rey MD, et al. Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan. J Dermatolog Treat. 2024. https:\/\/doi.org\/10.1080\/09546634.2023.2299598.","journal-title":"J Dermatolog Treat"},{"key":"1734_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03746-y","volume":"317","author":"E Lazaridou","year":"2025","unstructured":"Lazaridou E, Apalla Z, Ravanidis S, et al. Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics. Arch Dermatol Res. 2025;317:310. https:\/\/doi.org\/10.1007\/s00403-024-03746-y.","journal-title":"Arch Dermatol Res"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01734-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01734-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01734-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:35Z","timestamp":1780584815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01734-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1734"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01734-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jensen Yeung has served as a speaker, consultant, trialist, or received honoraria from AbbVie, Amgen, Apogee, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Fresenius Kabi, Galderma, Incyte, JAMP, Johnson & Johnson, Leo Pharma, Lilly, Pfizer, Sanofi Genzyme, Sun Pharma, and UCB. Jensen Yeung is an Editorial Board Member of\n                      Dermatology and Therapy\n                      , and was not involved in in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Parbeer Grewal has consulted, spoken for, or received grant funding and\/or honoraria from AbbVie, Amgen, Anacor, Arcutis, Arena Pharmaceuticals, Avillion, Bausch Health\/Valeant, Boehringer Ingelheim, BMS, Celgene, Cipher, Dermavant, Dermira, Eli Lilly, Galderma, GSK, Incyte, Innovaderm, Johnson & Johnson\/Janssen, Leo Pharma, Med Plan, Meiji Seika Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharmaceuticals, Takeda, UCB, Vitae. Perla Lansang has consulted, spoken for, or received honoraria from AbbVie, Amgen, Arcutis, Bausch Health\/Valeant, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galderma, Incyte, Janssen, Leo, Novartis, Pfizer, Regeneron, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, and UCB.\u00a0Ron Vender has consulted, spoken for, or received grant funding and\/or honoraria from AbbVie, Actelion, Amgen, Arcutis, Bausch-Health, Boehringer Ingelheim, BMS, Celgene, Centocor, Cipher, Demira, Dermavant, Eli Lilly, Galderma, GSK, Innovaderm, Janssen, Kabi-Care, Leo, Meiji, Merck, Novartis, Palladin, Pfizer, Regeneron, Sandoz, Sun Pharma, Takeda, UCB, and Viatris-Mylan. Marni Wiseman has served as consultant, speaker, advisory board member, and clinical trial investigator for AbbVie, Amgen, Arcutis, Asana BioSciences, AstraZeneca, Bausch Health, Bristol Myers Squibb, Celgene, Dermira, Eli Lilly, Galderma, Glenmark, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Principia, PRCL Research, Regeneron, Sanofi, UCB, and La Roche-Posay.\u00a0Rami Abou Zeinab and Maxime Barakat are employees at Bausch Health, Canada Inc. Vimal H Prajapati has been an advisor, consultant, and\/or speaker for: AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioJAMP\/JAMP Pharma, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Celltrion, Cipher, CorEvitas, Galderma, GlaxoSmithKline, Homeocan, Incyte, J&J Innovative Medicine, Janssen, Johnson & Johnson, Kenvue, Knight Therapeutics, LEO Pharma, Lilly, Medexus, Nia Health, Novartis, Organon, Paladin, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tribute, and UCB; investigator for: AbbVie, AnaptysBio, Apogee Therapeutics, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Galderma, Incyte, J&J Innovative Medicine, Janssen, LEO Pharma, Lilly, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, Q32 Bio, RAPT Therapeutics, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Vyne Therapeutics; received grants from: AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol for the Can Target Psoriasis study (Pro00063845) was reviewed and approved by the Advarra\u00ae institutional review board on May\u00a031, 2022, and adhered to the principles of the Declaration of Helsinki of 1964 and its later amendments, Good Clinical Practice guidelines, and relevant laws and regulations. Advarra\u00ae, established in 1983, offers institutional review board (IRB), institutional biosafety committee (IBC), and research quality and compliance consulting services in North America. A\u00a0Waiver\u00a0of Informed Consent was granted on the grounds that (1) the study involves the secondary use of existing information, (2) no identifiable information was included, and (3) no individual data was transmitted or stored outside of Canada.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}